ABCC9 and breast carcinoma: However, the use of this drug may not be recommended in epithelial ovarian cancer and relative metastatic spread, where the ABCC9 upregulation was significantly associated with longer progression-free survival of female patients (Fukushiro-Lopes et al., 2020) or in renal and breast cancers showing downregulation of the gene with drug–disease interaction.